These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38293275)

  • 21. The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).
    Cousins K; Chen CC; Sehanobish E; Jerschow E
    Adv Pharmacol; 2023; 97():423-444. PubMed ID: 37236766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease.
    Xu X; Reitsma S; Wang Y; Fokkens WJ
    Allergy; 2022 Dec; 77(12):3593-3605. PubMed ID: 36067036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease.
    Jakiela B; Soja J; Sladek K; Przybyszowski M; Plutecka H; Gielicz A; Licholai S; Aab A; Rebane A; Bochenek G
    J Allergy Clin Immunol; 2023 Apr; 151(4):953-965. PubMed ID: 36395984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.
    Llanos JP; Bell CF; Packnett E; Thiel E; Irwin DE; Hahn B; Ortega H
    J Asthma Allergy; 2019; 12():43-58. PubMed ID: 30774390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.
    Sousa J; Taborda-Barata L; Monteiro C
    Expert Opin Drug Saf; 2020 Jan; 19(1):99-106. PubMed ID: 31661986
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab.
    Shaker M; Briggs A; Dbouk A; Dutille E; Oppenheimer J; Greenhawt M
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):565-572. PubMed ID: 31626991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Conservative and Surgical Management in the Treatment of NSAID-Exacerbated Respiratory Disease.
    Sillanpää S; Numminen J
    Front Allergy; 2021; 2():659887. PubMed ID: 35387049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial neural network identifies nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD) cohort.
    Tyrak KE; Pajdzik K; Konduracka E; Ćmiel A; Jakieła B; Celejewska-Wójcik N; Trąd G; Kot A; Urbańska A; Zabiegło E; Kacorzyk R; Kupryś-Lipińska I; Oleś K; Kuna P; Sanak M; Mastalerz L
    Allergy; 2020 Jul; 75(7):1649-1658. PubMed ID: 32012310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
    Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
    Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
    Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
    Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
    Kowalski ML
    Curr Opin Pulm Med; 2019 Jan; 25(1):64-70. PubMed ID: 30489335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.